Cleland J G
Medical Research Council, Clinical Research Initiative in Heart Failure, University of Glasgow.
Br J Hosp Med. 1997;58(10):493-7.
Carvedilol is a non-selective beta-blocker, and the only one, in recent clinical trials, to have shown a clear reduction in mortality. It is suggested that, compared with other beta-blockers, carvedilol has additional advantageous effects in heart failure, and should be considered as part of the routine treatment of heart failure.
卡维地洛是一种非选择性β受体阻滞剂，并且是最近临床试验中唯一显示出能明显降低死亡率的药物。有人认为，与其他β受体阻滞剂相比，卡维地洛在心力衰竭方面具有额外的有益作用，应被视为心力衰竭常规治疗的一部分。
